Pharma
Pharma Co., Ltd., commonly referred to as Pharma, is a leading player in the pharmaceutical industry, headquartered in Japan (JP). Established in the early 2000s, the company has made significant strides in developing innovative healthcare solutions, primarily focusing on prescription medications and biopharmaceuticals. With a strong presence in Asia and expanding operations in Europe and North America, Pharma is renowned for its commitment to research and development. The company’s core products include advanced therapeutics for chronic diseases, which are distinguished by their efficacy and safety profiles. Pharma has garnered recognition for its contributions to the healthcare sector, achieving notable milestones such as successful drug approvals and collaborations with global research institutions. As a trusted name in pharmaceuticals, Pharma continues to enhance patient outcomes through its cutting-edge solutions and dedication to quality.
DitchCarbon Score
How does Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharma's score of 20 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharma's reported carbon emissions
In 2022, Pharma reported total carbon emissions of approximately 9,361,000 kg CO2e, combining Scope 1 and Scope 2 emissions. The breakdown includes about 7,312,000 kg CO2e from Scope 1 and approximately 2,049,000 kg CO2e from Scope 2 emissions. Regionally, significant contributions came from Switzerland with about 2,937,000 kg CO2e (Scope 1: 2,937,000 kg CO2e; Scope 2: 1,286,000 kg CO2e), South Africa with approximately 1,304,000 kg CO2e (Scope 1: 1,304,000 kg CO2e; Scope 2: 497,000 kg CO2e), and Ukraine with around 2,619,000 kg CO2e (Scope 1: 2,619,000 kg CO2e; Scope 2: 266,000 kg CO2e). Despite these emissions, Pharma has not disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or any formal climate pledges. This lack of publicly available reduction commitments places Pharma in a challenging position within the pharmaceutical industry's broader climate action context, where many companies are increasingly setting ambitious targets to reduce their carbon footprints.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | |
|---|---|
| Scope 1 | 7,312,000 |
| Scope 2 | 2,049,000 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
